Gerald L. Ray & Associates’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q3
$2.62M Sell
29,427
-300
-1% -$22.8K 0.33% 75
2017
Q2
$2.16M Sell
29,727
-1,200
-4% -$80.7K 0.28% 90
2017
Q1
$2.02M Sell
30,927
-1,950
-6% -$123K 0.28% 85
2016
Q4
$2.06M Sell
32,877
-229
-0.7% -$14K 0.3% 84
2016
Q3
$2.09M Sell
33,106
-1,339
-4% -$86.7K 0.31% 80
2016
Q2
$2.13M Sell
34,445
-1,800
-5% -$110K 0.34% 70
2016
Q1
$2.07M Buy
36,245
+1,141
+3% +$63.6K 0.34% 72
2015
Q4
$2.08M Buy
35,104
+50
+0.1% +$2.88K 0.33% 70
2015
Q3
$1.91M Buy
35,054
+398
+1% +$25.9K 0.32% 78
2015
Q2
$2.33M Buy
34,656
+1,970
+6% +$129K 0.35% 77
2015
Q1
$1.91M Sell
32,686
-1,800
-5% -$109K 0.29% 86
2014
Q4
$2.26M Hold
34,486
0.35% 70
2014
Q3
$1.99M Buy
34,486
+2,000
+6% +$111K 0.32% 81
2014
Q2
$1.83M Buy
32,486
+734
+2% +$38.5K 0.31% 83
2014
Q1
$1.63M Sell
31,752
-518
-2% -$26.2K 0.3% 84
2013
Q4
$1.7M Buy
32,270
+2
+0% +$98 0.32% 77
2013
Q3
$1.44M Sell
32,268
-497
-2% -$22K 0.3% 80
2013
Q2
$1.35M Buy
+32,765
New +$1.43M 0.3% 80

Other funds holding ABBV

Gerald L. Ray & Associates's ABBV Position: Q3 2017 in Review

Gerald L. Ray & Associates reduced its AbbVie (ABBV) stake by 1% in Q3 2017, selling an estimated $22.8K and leaving 29,427 shares worth $2.62M. The position accounts for 0.33% of the portfolio, ranked #75.

Gerald L. Ray & Associates first reported a position in ABBV in Q2 2013 and has held it in 18 quarters since. 1,797 funds tracked by Wall St. Rank hold ABBV as of Q3 2017.

  • Gerald L. Ray & Associates held 29,427 shares of AbbVie worth $2.62M as of Q3 2017.
  • Gerald L. Ray & Associates sold 300 AbbVie shares in Q3 2017, an estimated $22.8K.
  • AbbVie made up 0.33% of Gerald L. Ray & Associates's portfolio in Q3 2017, its #75 holding.
  • Gerald L. Ray & Associates first reported a position in AbbVie in Q2 2013 and has held it in 18 quarters since.
  • 1,797 funds tracked by Wall St. Rank held AbbVie as of Q3 2017.

Based on Gerald L. Ray & Associates's 13F filing for Q3 2017, filed 31 Oct 2017.